<DOC>
	<DOCNO>NCT01424540</DOCNO>
	<brief_summary>This single-center , randomize , two part , double-blind , crossover study healthy adult subject assess effect single dose GSK2336805 150mg cardiac function compare placebo use echocardiography primary assessment modality</brief_summary>
	<brief_title>Cross-Over Study Assess Cardiovascular Effects GSK2336805</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin less equal 1.5xUpper Limit Normal ( ULN ) . Healthy determine responsible experienced physician , base medical evaluation include [ medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include discretion Investigator find unlikely introduce additional risk factor interfere study procedure . Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation , oophorectomy , hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . Male subject female partner childbearing potential must agree use one contraception method list protocol . This criterion must follow time first dose study medication follow visit . Body weight great equal 50 kilogram ( kg ) men 45 kg woman . Body mass index ( BMI ) 18.530 inclusive allow . Capable give write informed consent , include compliance requirement restriction list consent form . Subject demonstrated adequate echocardiographic window . QTcB le 450 millisecond ( msec ) . A positive prestudy Hepatitis B surface antigen , positive Hepatitis C antibody , positive test HIV antibody result within 3 month screen . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . History regular alcohol consumption within 6 month study . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mililiters within 56 day period . Pregnant female determine positive [ serum urine ] hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . Subjects asthma history asthma . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice [ and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juice ] 7 day prior first dose study medication . Left ventricular ejection fraction le 55 % screening . The subject 's systolic blood pressure outside range 90140 , diastolic blood pressure outside range 4590 heart rate outside range 50100beats per minute female subject 45100 beat per minute male subject . Exclusion criterion screen ECG ( single repeat allow eligibility determination ) : MalesHeart rate le 45 great 100 beat per minute ( bpm ) . FemalesHeart rate le 50 great 100 bpm Evidence previous myocardial infarction ( Does include ST segment change associate repolarization ) . Any conduction abnormality ( include specific leave right complete bundle branch block , AV block [ 2nd degree high ] , Wolf Parkinson White [ WPW ] syndrome ) . Sinus Pauses great 3 second . Any significant arrhythmia , opinion principal investigator GSK medical monitor , interfere safety individual subject . Nonsustained sustain ventricular tachycardia ( great equal 3 consecutive ventricular ectopic beat ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>